Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00725387

Enrollment

214

Registered

2008-07-30

Start date

2007-08-31

Completion date

2019-06-30

Last updated

2019-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Brief summary

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients older than 18-year-old, diagnosed with cancer * Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them

Exclusion criteria

* Patients who cannot complete a PET/CT scan * Pregnant women * Healthy volunteers * Patients participating in other research studies The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.

Design outcomes

Primary

Measure	Time frame
Percent of patients with evidence of new lesions on combined F-18/F-18 FDG PET/CT.	not defined

Countries

Denmark, India, Portugal, South Africa, United States

Outcome results